Nature Biotechnology Contents: Volume 34 pp 573 - 672

If you are unable to see the message below, click here to view.

Advertisement Download immuno-oncology slides now from our 2 recent immuno-oncology webinars to learn key success factors for biomarker testing in immuno-oncology trials. Gain insights into genomic, anatomic pathology and flow cytometry applications to enhance your personalized immuno-oncology therapies and leverage this knowledge for companion diagnostic development. TABLE OF CONTENTS June 2016 Volume 34, Issue 6 Editorial News Bioentrepreneur Opinion and Comment Features News and Views Research Careers and Recruitment Advertisement Submit your proposal: Seeking Safe Drug-like small organic molecules for Human Use with Negligible Biological Effects. Deadline; 26th June. $20,000 award offered. See the full details and enter here. Subscribe   Facebook   RSS   Recommend to library   Twitter   Advertisement Single Cell Genomics (14-16 September 2016)  This conference on single cell genomics will bring together biologists, methods developers, computational modellers and genomics researchers interested in understanding biological variation at the single cell level. Deadlines: Bursary: 5 July/ Abstract: 12 July / Registration: 2 August    Advertisement BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities   Advertisement Nature Outlook Open Innovation In the competitive world of drug discovery and development, secrecy is no longer as important as it was. As it has become more difficult and costly to produce therapies, competitors have begun to view greater collaboration and openness as a way to improve the efficiency of research. Available free online Produced with support from Boehringer Ingelheim     Advertisement Immune Profiling in Health and Disease Presented by: Adaptive Biotechnologies | Nature Immunology | Nature Medicine | Nature Biotechnology | Nature Genetics October 3-5, 2016 | Bell Harbor International Conference Center, Seattle, WA, USA Register now!   Editorial Top No guarantees in translation   p573 doi:10.1038/nbt.3619 A drug company executive thinks academic institutions should give money back for research that turns out to be 'irreproducible'. News Top Gilead bets big on Nimbus' fatty liver disease drug   pp575 - 576 Mark Ratner doi:10.1038/nbt0616-575 Bristol-Myers Squibb locks into novel autoimmune strategy   pp577 - 579 Ken Garber doi:10.1038/nbt0616-577 Consortium nurtures ex vivo gene therapy firm   p578 Laura DeFrancesco doi:10.1038/nbt0616-578 Matchmaker for NIH-rejected grants   p579 Michael Francisco doi:10.1038/nbt0616-579 White House unveils National Microbiome Initiative   p580 Aaron Bouchie doi:10.1038/nbt0616-580a Amgen/UCB build on bone franchise with anti-sclerostin antibody   pp580 - 581 Suzanne Elvidge doi:10.1038/nbt0616-580b CRISPR-edited crops free to enter market, skip regulation   p582 Emily Waltz doi:10.1038/nbt0616-582 Tech billionaires fund new cancer centers   p583 doi:10.1038/nbt0616-583a AstraZeneca nabs genomics giants   p583 doi:10.1038/nbt0616-583b Around the world in a month   p583 doi:10.1038/nbt0616-583c Advertisement Nature Collection: Computational Biology Advances in technology across all areas of science have ushered in an era of big data, providing researchers with unprecedented opportunities to understand how biological systems function and interact. Access this collection free online for six months Produced with support from: IBM Research & IBM Watson Health   Bioentrepreneur Top Data page Research institute partnerships 2015   p584 Brady Huggett doi:10.1038/nbt.3610 Podcast First Rounders Podcast: Tom Maniatis   p584 Brady Huggett doi:10.1038/nbt.3611 Opinion and Comment Top Correspondence The president says patients should own their genetic data. He's wrong   pp585 - 586 Jorge L Contreras doi:10.1038/nbt.3608 Why patients shouldn't “own” their medical records   p586 John Rumbold and Barbara Pierscionek doi:10.1038/nbt.3552 Reply to Why patients shouldn't “own” their medical records   pp586 - 587 doi:10.1038/nbt.3615 Research that is fit to print   pp587 - 588 Harlan W Waksal doi:10.1038/nbt.3577 Reply to Research that is fit to print   p588 doi:10.1038/nbt.3612 Secure cloud computing for genomic data   pp588 - 591 Somalee Datta, Keith Bettinger and Michael Snyder doi:10.1038/nbt.3496 The contribution of cell cycle to heterogeneity in single-cell RNA-seq data   pp591 - 593 Andrew McDavid, Greg Finak and Raphael Gottardo doi:10.1038/nbt.3498 Reply to The contribution of cell cycle to heterogeneity in single-cell RNA-seq data   pp593 - 595 doi:10.1038/nbt.3607 Features Top Cancer moonshot countdown   pp596 - 599 Douglas Lowy, Dinah Singer, Ron DePinho, Gregory C Simon and Patrick Soon-Shiong doi:10.1038/nbt.3616 Nature Biotechnology asks representatives from three different cancer 'moonshot' initiatives to outline their visions. Gene therapy's out-of-body experience   pp600 - 607 Christopher Thomas Scott and Laura DeFrancesco doi:10.1038/nbt.3592 With an approval likely at the EMA, ex vivo gene therapy in hematopoietic stem cells appears poised for prime time. Biotech's wellspring—a survey of the health of the private sector in 2015   pp608 - 615 Brady Huggett doi:10.1038/nbt.3600 The eagerness of non-traditional biotech investors made for another good year for the industry. Will it continue? Patents The morality and ethics governing CRISPR-Cas9 patents in China   pp616 - 618 Yaojin Peng doi:10.1038/nbt.3590 Chinese patent law may not be equipped to deal with the potential moral issues raised by gene-editing technology. Recent patents in organoids   p619 doi:10.1038/nbt.3618 Advertisement nature.com webcasts Nature Publishing Group presents a custom webcast on: Overcoming current challenges with 3D cell culturing Wednesday June 15, 2016 8AM PDT, 11AM EDT, 4PM BST, 5PM CEST Register for the webcast and live Q&A session Sponsored by: Lonza Bioscience Solutions Custom webcast: sponsor retains sole responsibility for content     News and Views Top Resistance from relatives   pp620 - 621 Andrew Bent doi:10.1038/nbt.3591 Crops are made resistant to pathogens such as wheat stem rust, Asian soybean rust and potato late blight by methods to access the pool of resistance genes present in related plants. See also: Research by Steuernagel et al. | Research by Witek et al. | Research by Kawashima et al. Comparing CRISPR and RNAi-based screening technologies   pp621 - 623 Benjamin E Housden and Norbert Perrimon doi:10.1038/nbt.3599 Two studies provide an experimental side-by-side comparison of genetic screening methods. See also: Research by Evers et al. | Research by Morgens et al. The minimal genome comes of age   pp623 - 624 Claudia E Vickers doi:10.1038/nbt.3593 A genome smaller than any known natural or reduced genome has been designed, synthesized and shown capable of sustaining self-replication in a free-living environment. Research Highlights   p624 doi:10.1038/nbt.3595 Biotechnology JOBS of the week Postdoctoral Positions - Modeling vascular development and disease in the zebrafish University of Massachusetts Executive Director of the Biodesign Institute Arizona State University, Biodesign Institute Exciting PhD Positions in Modern Biology VBC PhD Programme More Science jobs from Research Top Perspective The US regulatory and pharmacopeia response to the global heparin contamination crisis   pp625 - 630 Anita Y Szajek, Edward Chess, Kristian Johansen, Gyongyi Gratzl, Elaine Gray et al. doi:10.1038/nbt.3606 Brief Communications CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes   pp631 - 633 Bastiaan Evers, Katarzyna Jastrzebski, Jeroen P M Heijmans, Wipawadee Grernrum, Roderick L Beijersbergen et al. doi:10.1038/nbt.3536 CRISPR knockout screens outperform shRNA and CRISPR-interference screens in a side-by-side comparison. See also: News and Views by Housden & Perrimon Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes   pp634 - 636 David W Morgens, Richard M Deans, Amy Li and Michael C Bassik doi:10.1038/nbt.3567 A side-by-side comparison of CRISPR/Cas9 and RNAi screens for essential genes reveals method-specific differences in performance. See also: News and Views by Housden & Perrimon Article Wishbone identifies bifurcating developmental trajectories from single-cell data   pp637 - 645 Manu Setty, Michelle D Tadmor, Shlomit Reich-Zeliger, Omer Angel, Tomer Meir Salame et al. doi:10.1038/nbt.3569 Cell differentiation is accurately modeled by an algorithm that orders single cells along branched developmental trajectories. Letters Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch   pp646 - 651 Benjamin L Oakes, Dana C Nadler, Avi Flamholz, Christof Fellmann, Brett T Staahl et al. doi:10.1038/nbt.3528 A small-molecule-inducible Cas9 variant with very low background activity is identified by screening for sites that can tolerate domain insertions. Rapid cloning of disease-resistance genes in plants using mutagenesis and sequence capture   pp652 - 655 Burkhard Steuernagel, Sambasivam K Periyannan, Inmaculada Hernandez-Pinzon, Kamil Witek, Matthew N Rouse et al. doi:10.1038/nbt.3543 A method for rapid cloning of plant disease-resistance genes could provide sustainable, genetic solutions to crop pests and pathogens in place of agrichemicals. See also: News and Views by Bent Accelerated cloning of a potato late blight-resistance gene using RenSeq and SMRT sequencing   pp656 - 660 Kamil Witek, Florian Jupe, Agnieszka I Witek, David Baker, Matthew D Clark et al. doi:10.1038/nbt.3540 A method for rapid cloning of plant disease-resistance genes could provide sustainable genetic solutions to crop pests and pathogens in place of agrichemicals. See also: News and Views by Bent A pigeonpea gene confers resistance to Asian soybean rust in soybean   pp661 - 665 Cintia G Kawashima, Gustavo Augusto Guimaraes, Sonia Regina Nogueira, Dan MacLean, Doug R Cook et al. doi:10.1038/nbt.3554 Soybean is made resistant to Asian soybean rust using a gene cloned from pigeonpea, showing that legumes may contain a reservoir of disease-resistance genes. See also: News and Views by Bent Errata Erratum: 20 years of Nature Biotechnology research tools   p666 Anna Azvolinsky, Laura DeFrancesco, Emily Waltz and Sarah Webb doi:10.1038/nbt0616-666a Erratum: 20 years of Nature Biotechnology biomedical research   p666 Anna Azvolinsky, Charles Schmidt, Emily Waltz and Sarah Webb doi:10.1038/nbt0616-666b Erratum: When biotech goes bad   p666 John Hodgson doi:10.1038/nbt0616-666c Erratum: Community crystal gazing   p666 Anu Acharya, Kate Bingham, Jay Bradner, Wylie Burke, R Alta Charo et al. doi:10.1038/nbt0616-666d Corrigendum Corrigendum: Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates   p666 Arturo J Vegas, Omid Veiseh, Joshua C Doloff, Minglin Ma, Hok Hei Tam et al. doi:10.1038/nbt0616-666e Careers and Recruitment Top Compensation inflation remains consistent at private life science companies   pp667 - 670 Bruce Rychlik doi:10.1038/nbt.3604 Non-founder total target cash compensation increased 3.3% at private life science companies in 2015. People People   p672 doi:10.1038/nbt.3617 Advertisement BioPharma Dealmakers  A supplement to Nature Biotechnology & Nature Reviews Drug Discovery Sign up to our NEW networking forum to connect with life sciences companies and partnering professionals looking for dealmaking opportunities.  Stay up to date on emerging therapeutic areas  Ask for advice from our editors and experts in the field SIGN UP NOW   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.